MetaCap

BioStem Technologies (BSEM) vs Pluri (PLUR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Pluri (PLUR) has outperformed BioStem Technologies (BSEM) over the past year, losing 75.3% versus a loss of 84.0%. Over five years, BSEM leads with a -55.9% price change compared with -95.6% for PLUR. Pluri is the larger company by market cap ($13.5 million vs $12.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BSEM-83.98%PLUR-75.26%
+116%+11%-94%
Nov 21, 20251 yearNov 20, 2026
BSEM-25.28%PLUR-95.53%
+2716%+1243%-229%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BSEM versus PLUR key metrics
MetricBSEMPLUR
Share price$0.6351$0.94
Market cap$12.18M$13.51M
1-day change-10.23%-3.07%
YTD return-83.33%-68.56%
1-year return-83.98%-75.26%
5-year return-55.90%-95.63%
P/E ratio (TTM)0.72—
Forward P/E2.19—
EPS (TTM)$0.88$-2.65
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.02M
Revenue growth (YoY)—-23.95%
Net income (latest FY)—$-23.82M
Gross margin—44.59%
Operating margin—-2454.53%
Net margin—-2344.59%
52-week high$8.40$3.94
52-week low$0.5347$0.85
Distance from 52-week high-92.44%-76.14%
Analyst consensusnone—
Avg. price target upside+1002.19%—
Average volume194.93K36.98K
Shares outstanding19.18M14.38M
Employees7392
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About BioStem Technologies

BSEM stock →

BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 73 employees

About Pluri

PLUR stock →

Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and an immunotherapy platform.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 92 employees

BSEM vs PLUR FAQ

Which is bigger, BioStem Technologies or Pluri?

Pluri (PLUR) is larger, with a market capitalization of $13.51M compared with $12.18M for BioStem Technologies (BSEM).

Which stock has performed better over the past year, BSEM or PLUR?

PLUR returned -75.26% over the past 12 months, compared with -83.98% for BSEM (price return, excluding dividends). Past performance does not predict future results.

Are BioStem Technologies and Pluri in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons